Graves' disease and Graves' orbitopathy following COVID-19.

Lanzolla, G; Marcocci, C; Marinò, M

Lanzolla, G; Marcocci, C; Marinò, M.

Lanzolla G; Department of Clinical and Experimental Medicine, Endocrinology Unit II, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
Marcocci C; Department of Clinical and Experimental Medicine, Endocrinology Unit II, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
Marinò M; Department of Clinical and Experimental Medicine, Endocrinology Unit II, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. michele.marino@med.unipi.it.

J Endocrinol Invest ; 44(9): 2011-2012, 2021 Sep.

Article in English | MEDLINE | ID: covidwho-1219509

Subject(s)

Autoimmunity/immunology; COVID-19/immunology; Graves Disease/immunology; Graves Ophthalmopathy/immunology; SARS-CoV-2; Adult; Female; Humans; Stress, Psychological/immunology

Keywords

Autoimmunity; COVID-19; Graves' disease; Graves' orbitopathy; SARS-CoV-2; Thyroid

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmunity / Graves Disease / Graves Ophthalmopathy / SARS-CoV-2 / COVID-19 Type of study: Case report Limits: Adult / Female / Humans Language: English Journal: J Endocrinol Invest Year: 2021 Document Type: Article Affiliation country: S40618-021-01576-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google